Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Family Medicine | Gastroenterology | Infections | Internal Medicine | Pharmacy | Journal

Back to Journal Articles

Experimental HCV Drug Combination Shows Potential

Last Updated: October 15, 2010.

 

Oral combination demonstrates promising antiviral activity, is well-tolerated and safe

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
An experimental oral drug combination appears to be well-tolerated and safe, showing promising antiviral activity for the treatment of patients with chronic hepatitis C virus (HCV) infection, according to a study published online Oct. 15 in The Lancet.

FRIDAY, Oct. 15 (HealthDay News) -- An experimental oral drug combination appears to be well-tolerated and safe, showing promising antiviral activity for the treatment of patients with chronic hepatitis C virus (HCV) infection, according to a study published online Oct. 15 in The Lancet.

Edward J. Gane, M.D., of Auckland Clinical Studies in New Zealand, and colleagues systematically evaluated the safety, tolerability, and antiviral activity of an all-oral combination treatment with two experimental anti-HCV drugs, RG7128 (a nucleoside polymerase inhibitor) and danoprevir (a protease inhibitor), in patients with chronic HCV infection. The investigators randomized 88 patients to the drug treatment regimen or placebo.

At the highest combination doses tested (1,000 mg RG7128 and 900 mg danoprevir twice daily), the investigators found that the median change in HCV RNA concentration from baseline to day 14 was -5.1 log10 IU/mL in patients who had never been treated before and -4.9 log10 IU/mL in patients who had shown no response to previous standard treatment, compared with an increase of 0.1 log10 IU/mL in the placebo group. The combined treatment approach showed no evidence of resistance and was not associated with any treatment-related severe adverse events.

"This oral combination of a nucleoside analogue polymerase inhibitor and protease inhibitor holds promise as an interferon-free treatment for chronic HCV," the authors write.

The study was funded by Roche, with multiple authors disclosing financial relationships with the company. A few authors also disclosed financial relationships with other pharmaceutical companies.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2010 HealthDay. All rights reserved.


Previous: "Natural" Weight Loss Products Pose Danger Next: Individual BP Goal May Affect Mortality for Dialysis Patients

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2013
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.